{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T05:50:16Z","timestamp":1771048216017,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,2,6]],"date-time":"2019-02-06T00:00:00Z","timestamp":1549411200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s11255-019-02090-9","type":"journal-article","created":{"date-parts":[[2019,2,6]],"date-time":"2019-02-06T09:54:53Z","timestamp":1549446893000},"page":"417-424","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Which antimuscarinic agents used in the treatment of overactive bladder increase heart rate? a prospective randomized clinical trial"],"prefix":"10.1007","volume":"51","author":[{"given":"Bulent","family":"Cetinel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bulent","family":"Onal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet Hamza","family":"Gultekin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammed","family":"Guzelsoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fethi Ahmet","family":"Turegun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murat","family":"Dincer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,2,6]]},"reference":[{"key":"2090_CR1","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/nau.10052","volume":"21","author":"P Abrams","year":"2002","unstructured":"Abrams P, Cardozo L, Fall M et al (2002) The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21:167\u2013178","journal-title":"Neurourol Urodyn"},{"key":"2090_CR2","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1046\/j.1464-410x.2001.02228.x","volume":"87","author":"I Milsom","year":"2001","unstructured":"Milsom I, Abrams P, Cardozo L et al (2001) How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87:760\u2013766","journal-title":"BJU Int"},{"key":"2090_CR3","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","volume":"20","author":"WF Stewart","year":"2003","unstructured":"Stewart WF, Van Rooyen JB, Cundiff GW et al (2003) Prevalence and burden of overactive bladder in the United States. World J Urol 20:327\u2013336","journal-title":"World J Urol"},{"issue":"1","key":"2090_CR4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11255-008-9403-2","volume":"41","author":"MR Safarinejad","year":"2009","unstructured":"Safarinejad MR (2009) Prevalence of the overactive bladder among Iranian women based on the International Continence Society definition: a population-based study. Int Urol Nephrol 41(1):35\u201345","journal-title":"Int Urol Nephrol"},{"issue":"10","key":"2090_CR5","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1007\/s11255-015-1100-3","volume":"47","author":"H Hashim","year":"2015","unstructured":"Hashim H, Beusterien K, Bridges JF, Amos K, Cardozo L (2015) Patient preferences for treating refractory overactive bladder in the UK. Int Urol Nephrol 47(10):1619\u20131627","journal-title":"Int Urol Nephrol"},{"key":"2090_CR6","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/sj.bjp.0706780","volume":"148","author":"P Abrams","year":"2006","unstructured":"Abrams P, Andersson KE, Buccafusco JJ et al (2006) Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 148:565\u2013578","journal-title":"Br J Pharmacol"},{"key":"2090_CR7","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/j.1365-2125.2010.03813.x","volume":"72","author":"K-E Andersson","year":"2011","unstructured":"Andersson K-E, Campeau L, Olshansky B (2011) Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction. Br J Clin Pharmacol 72:186\u2013196","journal-title":"Br J Clin Pharmacol"},{"key":"2090_CR8","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1038\/sj.bjp.0705338","volume":"139","author":"RD Harvey","year":"2003","unstructured":"Harvey RD, Belevych AE (2003) Muscarinic regulation of cardiac ion channels. Br J Pharmacol 139:1074\u20131084","journal-title":"Br J Pharmacol"},{"key":"2090_CR9","first-page":"1005","volume":"17","author":"A Hozawa","year":"2004","unstructured":"Hozawa A, Ohkubo T, Kikuya M et al (2004) Prognostic value of home heart rate for cardiovascular mortality in the general population: the Ohasama Study. Am J Hypertens 17:1005\u20131010","journal-title":"Am J Hypertens"},{"key":"2090_CR10","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.amjcard.2008.08.071","volume":"103","author":"X Jouven","year":"2009","unstructured":"Jouven X, Empana JP, Escolano S et al (2009) Relation of heart rate at rest and long-term (> 20 years) death rate in initially healthy middle-aged men. Am J Cardiol 103:279\u2013283","journal-title":"Am J Cardiol"},{"key":"2090_CR11","doi-asserted-by":"publisher","first-page":"b219","DOI":"10.1136\/bmj.b219","volume":"338","author":"J Hsia","year":"2009","unstructured":"Hsia J, Larson JC, Ockene JK et al (2009) Resting heart rate as a low tech predictor of coronary events in women: prospective cohort study. BMJ 338:b219","journal-title":"BMJ"},{"key":"2090_CR12","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.eururo.2008.06.047","volume":"54","author":"CR Chapple","year":"2008","unstructured":"Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein DA (2008) The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and metaanalysis. Eur Urol 54:543\u2013562","journal-title":"Eur Urol"},{"key":"2090_CR13","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.eururo.2008.06.080","volume":"54","author":"G Novara","year":"2008","unstructured":"Novara G, Galfano A, Secco S et al (2008) A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol 54:740\u2013763","journal-title":"Eur Urol"},{"issue":"12","key":"2090_CR14","doi-asserted-by":"publisher","first-page":"806","DOI":"10.4111\/kju.2013.54.12.806","volume":"54","author":"B Cetinel","year":"2013","unstructured":"Cetinel B, Onal B (2013) Rationale for the use of anticholinergic agents in overactive bladder with regard to central nervous system and cardiovascular system side effects. Korean J Urol 54(12):806\u2013815","journal-title":"Korean J Urol"},{"key":"2090_CR15","first-page":"113","volume":"21","author":"T Tarcan","year":"2012","unstructured":"Tarcan T, Mangir N, Ozgur MO, Akbal C (2012) Validation study of Turkish version of OAB-V8 overactive bladder questionnaire. Uroloji Bulteni 21:113\u2013116","journal-title":"Uroloji Bulteni"},{"key":"2090_CR16","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1464-410X.2009.09073.x","volume":"106","author":"KE Andersson","year":"2010","unstructured":"Andersson KE, Sarawate C, Kahler KH et al (2010) Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder. BJU Int 106:268\u2013274","journal-title":"BJU Int"},{"key":"2090_CR17","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1097\/01.ju.0000127742.73136.0c","volume":"171","author":"N Zinner","year":"2004","unstructured":"Zinner N, Gittelman M, Harris R, Susset J, Kanelos A, Auerbach S, Trospium Study Group (2004) Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 171:2311\u20132315","journal-title":"J Urol"},{"key":"2090_CR18","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.urology.2005.08.017","volume":"67","author":"D Rudy","year":"2006","unstructured":"Rudy D, Cline K, Harris R, Goldberg K, Dmochowski R (2006) Multicenter phase III trial studying trospium chloride in patients with overactive bladder. Urology 67:275\u2013280","journal-title":"Urology"},{"key":"2090_CR19","first-page":"461","volume":"43","author":"HP Breuel","year":"1993","unstructured":"Breuel HP, M\u00fcrtz G, Bondy S, Horkulak J, Gianetti BM (1993) Safety and tolerance of trospium chloride in the high dose range. Arzneimittelforschung 43:461\u2013464","journal-title":"Arzneimittelforschung"},{"key":"2090_CR20","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/1074248408325404","volume":"13","author":"B Olshansky","year":"2008","unstructured":"Olshansky B, Ebinger U, Brum J et al (2008) Differential pharmacological effects of antimuscarinic drugs on heart rate: a randomized, placebo-controlled, doubleblind, cross-over study with tolterodine tartrate and darifenacin in healthy participants> or = 50 years old. J Cardiovasc Pharmacol Ther 13:241\u2013251","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"2090_CR21","doi-asserted-by":"publisher","DOI":"10.3834\/uij.1944-5784.2009.08.07","author":"B Olshansky","year":"2009","unstructured":"Olshansky B, Spierings E, Brum J et al (2009) Validation of the differential cardiovascular effects of the antimuscarinic agents, darifenacin and tolterodine tartrate, in a randomized, placebo-controlled, 3-way crossover study. UroToday Int J. \n                    https:\/\/doi.org\/10.3834\/uij.1944-5784.2009.08.07","journal-title":"UroToday Int J"},{"key":"2090_CR22","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s00345-010-0513-y","volume":"28","author":"M Schiffers","year":"2010","unstructured":"Schiffers M, Sauermann P, Schurch B, Mehnert U (2010) The effect of tolterodine tartrate 4 and 8 mg on the heart rate variability in healthy subjects. World J Urol 28:651\u2013656","journal-title":"World J Urol"},{"key":"2090_CR23","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.eururo.2007.07.009","volume":"52","author":"C Chapple","year":"2007","unstructured":"Chapple C, Van KP, Tubaro A et al (2007) Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol 52:1204\u20131212","journal-title":"Eur Urol"},{"key":"2090_CR24","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1442-2042.2006.01387.x","volume":"13","author":"P Abrams","year":"2006","unstructured":"Abrams P, Cardozo L, Chapple C, Serdarevic D, Hargreaves K, Khullar V (2006) 1032 study group. Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome. Int J Urol 13:692\u2013698","journal-title":"Int J Urol"},{"issue":"6","key":"2090_CR25","doi-asserted-by":"publisher","first-page":"505","DOI":"10.2165\/00002018-200831060-00005","volume":"31","author":"MC Michel","year":"2008","unstructured":"Michel MC, Wetterauer U, Vogel M, de la Rosette JJMCH (2008) Cardiovascular safety and overall tolerability of solifenacin in routine clinical use. Drug Saf 31(6):505\u2013514","journal-title":"Drug Saf"},{"key":"2090_CR26","first-page":"02","volume":"48","author":"CR Chapple","year":"2005","unstructured":"Chapple CR, Abrams P (2005) Comparison of darifenacin and oxybutynin in patients with overactive bladder: assessment of ambulatory urodynamics and impact on salivary flow. Eur Urol 48:02\u20139","journal-title":"Eur Urol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11255-019-02090-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-019-02090-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-019-02090-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T00:11:42Z","timestamp":1580947902000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11255-019-02090-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,6]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["2090"],"URL":"https:\/\/doi.org\/10.1007\/s11255-019-02090-9","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,6]]},"assertion":[{"value":"23 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Authors of this study have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This open-label, prospective, multi-center, randomized and controlled follow-up study has institutional approval from Cerrahpasa School of Medicine Ethical Commitee with IRB number of 671\/2014.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}